Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 4Other hematologic neoplasm 2Myeloid 2Head & Neck 2Gastrointestinal 2Tumor-Agnostic 1Sarcoma 1Endocrine 1Dermatologic 1CNS 1

Conditions

Skin Neoplasms 1Carotid Intimal Medial Thickness 1 1Carcinoma, Squamous Cell 1

Interventions

Ipilimumab 123pembrolizumab 101Nivolumab 100aldesleukin 89Cyclophosphamide 85fludarabine phosphate 64Interleukin-2 58Dacarbazine 573-ingenyl angelate 42Vemurafenib 39Temozolomide 39Imiquimod 39trametinib 37sargramostim 37Peripheral Blood Stem Cell Transplantation 36incomplete Freund's adjuvant 35dabrafenib 32fludarabine 31Radiotherapy 31Aminolevulinic Acid 30Bevacizumab 29Carboplatin 28Whole-Body Irradiation 25Photochemotherapy 25Paclitaxel 25Filgrastim 25Biopsy 25Interferon-alpha 24Cisplatin 23Sorafenib 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Pioglitazone × Dermatologic × Clear all
NCT02347813 2020-06-23

Preventing Squamous Cell Skin Cancer

University of Rochester

Phase 2 Completed
12 enrolled 10 charts
Dermatologic

Carotid Intimal Medial Thickness 1, Carcinoma, Squamous Cell, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡